Q3 Interim Management Statement 2011/12
The Johnson Matthey group continued to make further good progress in the third quarter. Compared with the same period last year, sales excluding precious metals (sales) were up 22% at £649 million and underlying profit before tax increased by 34% to £104.3 million.
The Fine Chemicals Division continued its strong performance with sales up 15% to £62 million and good growth in operating profit. The Active Pharmaceutical Ingredient (API) Manufacturing businesses performed well aided by sales of a new API for the treatment of drug addiction.
For further information, please click here.